<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870933</url>
  </required_header>
  <id_info>
    <org_study_id>LB.02.01/VII/086/KEP.007.EV</org_study_id>
    <nct_id>NCT02870933</nct_id>
  </id_info>
  <brief_title>Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery</brief_title>
  <official_title>The Effect of Transepicardial Augmentation on Transseptal Autologous CD 133+ Bone Marrow Cell Implantation to Myocardial Perfusion in Patient Following Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cardiovascular Center Harapan Kita Hospital Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cardiovascular Center Harapan Kita Hospital Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart Failure has several etiologies and one of them is coronary artery disease. Coronary
      artery bypass grafting (CABG) is one of revascularizations method which has been used for
      decades in coronary artery disease theraphy. However, data about coronary artery bypass
      grafting shows that post-CABG patients still have low ejection fraction. For the last decade,
      there have been a lot of studies about the using of stem cells to increase heart
      contractility and reverse the heart remodelling process. In this study, we use CD 133+ bone
      marrow stem cells which has been proved to have higher angiogenesis potential. The stem cells
      is given during CABG by injection transepicardial and transseptal. The purpose of this study
      is to determine whether transpicardial and transseptal injection of CD 133+ bone marrow stem
      cells can improve myocardial perfusion in patient with low ejection fraction following CABG
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study sample : patient with low ejection fraction indicated for CABG surgery in NCCHK who
      fulfill inclusion and exclusion criteria

      Sampling method : first we use consecutive method to find subject with male sex and age
      40-70. After that, we use simple random sampling to allocate each subject to each group.

      Total samples is 13 for each group. To anticipated drop out rate 10%, total sample is 15 for
      each group.

      Intervention and measurement :

      Control group will only receive CABG surgery. Study group will receive CBAG surgery and stem
      cell implantation. Stem cell aspiration will be performed 1 day before CABG procedure. Before
      aspiration, patients will be given local anesthetic and light sedation. Stem cell will be
      collected from posterior iliac crest. Total aspirate 190 cc. Stem cell CD133+ will be
      separated using CliniMACSÂ® Magnetic Separation Device after labelled with Magnetic microbeads
      - anti CD133 labelling.

      Myocardial perfusion reserve index will be measure using MRI. MPRI value will be obtained
      globally and segmentally in each 16 ventricle segments VEGF plasma level will be measured
      using sandwich Enzyme-linked Immunosorbent Assay method.

      Ejection fraction, left ventricle dimension, and scar size will be measured using MRI.

      Quality of life will be measured using Minnesota Living With Heart Failure Questionnaire.

      Statistical analysis is done using IBM SPSS Statistics version 21.0 (SPSS inc, Chicago, IL,
      USA). Numerical data will be presented in either mean/standard deviation or median/min-max
      depend on distribution of data. Hypothesis test for numeric variable is done using
      paired/non-paired T test or Mann-Whitney/Wilcoxon depend on normality of data. Normality test
      is done using Shapiro-Wilk test. Hypothesis test for category varible is done using
      chi-square or fischer test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Defect Perfusion</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Number of heart wall segments with perfusion defect measured by MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Left ventricular ejection fraction (LVEF) measured by MRI. Normal range of LVEF ranges from 50% to 70%. Borderline LVEF ranges from 41% to 49% Reduced LVEF ranges &lt; 41%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six Minutes Walking Test</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Quality of life will be assessed using Six minutes walking test, to see the changes of six minutes walking test before and after intervention Distances reported for healthy individuals ages 40 yo 85 years range from 400 to 700 m..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wall Motion Score Index</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Cardiac wall motion abnormality will be measured using Wall Motion Score Index with MRI. Each myocardial segment is assigned a score from 1 to 4. The 16 segment model of myocardial segmentation is recommended.
A WMSI of 1.0 is considered normokinetic. A WMSI of 1.5 is considered mild hypokinesia A WMSI of 2.0 is considered hypokinesia A WMSI of 2.5 is considered severe hypokinesia A WMSI of 3.0 is considered akinetic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Scar Size</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Percentage of myocardial scar size proportion measured by MRI to quantify and define the extent/transmurality of scar tissue, the following definitions were used
spatial (circumferential) extent, the number of affected segments
nontransmurality, the number of segmments with a segmental scar score of 1 or 2, and transmurality, the number of segments with a segmental scar score of 3 or 4
total score, summed segmental scar scores per patient divided by 17 (which reflects the damage per patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Endothelial Growth Factor</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Cytokine that has important role for angiogenesis. Normal range for plasma VEGF is 0-115 pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle End Systolic Volume</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Left ventricle end-systolic volume is the volume of blood in a left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole.
Normal LVESV ranges is 37 - 57 mililiters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure Questionnaire</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Quality of life assessed using Minnesota Living With Heart Failure Questionnaire consist of 21 questions, to see the changes before and after intervention.
Minimum score = 0, Maximum score = 105 Higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle End Diastolic Volume</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Left ventricle end-diastolic volume is the volume of blood in the left ventricle at end load or filling in (diastole) or the amount of blood in the ventricle just before systole.
Normal ranges of LVEDV is 121 - 163 mililiters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this arm will receive Transepicardial with Transseptal CD 133+ Implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>this arm will not receive Transepicardial with Transseptal CD 133+ Implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Transepicardial with Transseptal CD 133+ Implantation</intervention_name>
    <description>Transepicardial with Transseptal CD 133+ Implantation</description>
    <arm_group_label>subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with coronary artery disease 3 vessels disease indicated for CABG

          -  LVEF &lt; 35% which has been confirmed by MRI

          -  Patients with akinetic or hypokineic segment, and left ventricle myocardial
             hypoperfusion confirmed in MRI

          -  has signed informed consent

        Exclusion Criteria:

        Emergency CABG Ungraftable coronary artery Acute myocardial Infarct (&lt;14 days) Valve
        disease which need surgery repair Contraindicated for MRI High degree ventricular arrhytmia
        Coagulation disorder HIV positive patient, Hepatitis B + patients, HCV + patients AST/ALT &gt;
        1,5 upper normal value Creatinine &gt; 2 g/dl. Malignancy

        Drop out criteria :

        Aortic cross clamp &gt;120 minutes and CABG total time &gt;180
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tri Wisesa Soetisna, MD, MHA</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cardiovascular Center Harapan Kita</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiovascular Center Harapan Kita</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>11420</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 7, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <results_first_submitted>July 2, 2019</results_first_submitted>
  <results_first_submitted_qc>March 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2020</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cardiovascular Center Harapan Kita Hospital Indonesia</investigator_affiliation>
    <investigator_full_name>Tri Wisesa Soetisna, MD, MHA</investigator_full_name>
    <investigator_title>Director of Human Capital and General Affairs of National Cardiac Center</investigator_title>
  </responsible_party>
  <keyword>CD 133+</keyword>
  <keyword>Transepicardial with Transseptal Implantation</keyword>
  <keyword>CABG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02870933/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02870933/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CABG + Transepicardial With Transseptal CD 133+ Implantation</title>
          <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>this arm will receive CABG only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CABG + Transepicardial With Transseptal CD 133+ Implantation</title>
          <description>this arm will receive Transepicardial with Transseptal CD 133+ Implantation</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>this arm will not receive Transepicardial with Transseptal CD 133+ Implantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.92" spread="8.95"/>
                    <measurement group_id="B2" value="57.46" spread="6.33"/>
                    <measurement group_id="B3" value="56.69" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Indonesia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <description>Systolic blood pressure is created when the heart beats, squeezes and push blood through arteries. The unit of measure is mmHg.
Normal range for systolic pressure is &lt; 120 mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.92" spread="14.37"/>
                    <measurement group_id="B2" value="126.5" spread="19.60"/>
                    <measurement group_id="B3" value="123.38" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <description>Pressure blood exerts within arteries between heart beats. Normal range for diastolic pressure is &lt; 80 mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.00" spread="12.03"/>
                    <measurement group_id="B2" value="72.46" spread="15.36"/>
                    <measurement group_id="B3" value="75.04" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <description>Smoking as one of coronary artery disease risk factor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia</title>
          <description>Dyslipidemia as one of coronary artery disease risk factor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <description>Hypertension as one of coronary artery disease risk factor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopause</title>
          <description>Menopause as one of coronary artery disease risk factor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <description>Diabetes as one of coronary artery disease risk factor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Random blood sugar level</title>
          <description>The reference values for a &quot;normal&quot; random glucose test in an average adult are 80-140 mg/dl, between 140-2000 mg/dl is considered pre-diabetis, and &gt;200 mg/dl is considered diabetes according ADA guidelines.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.85" spread="38.89"/>
                    <measurement group_id="B2" value="136.85" spread="39.0"/>
                    <measurement group_id="B3" value="131.85" spread="38.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA grade III-IV</title>
          <description>NYHA (New York Heart Association) is classification for heart failure. Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.
Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest.
Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CCS grade III-IV</title>
          <description>Canadian Cardiovascular Society grading of angina pectoris. I : Ordinary physical activity does not cause angina II: Slight limitation of ordinary activity III: Marked limitation of ordinary physical activity IV: Inability to carry on any physical activity without discomfort, anginal syndrome may be present at rest</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Six minutes walk test</title>
          <description>6-min walk test is sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297.08" spread="72.56"/>
                    <measurement group_id="B2" value="308.92" spread="79.37"/>
                    <measurement group_id="B3" value="303.0" spread="74.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricle Ejection Fraction</title>
          <description>Left ventricular ejection fraction (LVEF) measured by MRI. Normal range of LVEF ranges from 50% to 70%. Borderline LVEF ranges from 41% to 49% Reduced LVEF ranges &lt; 41%</description>
          <units>Percentage of Ejection Fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.88" spread="5.66"/>
                    <measurement group_id="B2" value="30.18" spread="3.85"/>
                    <measurement group_id="B3" value="28.03" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricle End-Systolic Volume</title>
          <description>Left ventricle end-systolic volume is the volume of blood in a left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole.
Normal LVESV ranges is 37 - 57 mililiters.</description>
          <units>mililiters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115.87" spread="35.94"/>
                    <measurement group_id="B2" value="141.05" spread="27.77"/>
                    <measurement group_id="B3" value="128.46" spread="33.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricle End-Diastolic Volume</title>
          <description>Left ventricle end-diastolic volume is the volume of blood in the left ventricle at end load or filling in (diastole) or the amount of blood in the ventricle just before systole.
Normal ranges of LVEDV is 121 - 163 mililiters</description>
          <units>mililiters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.10" spread="47.46"/>
                    <measurement group_id="B2" value="200.89" spread="37.10"/>
                    <measurement group_id="B3" value="178.5" spread="47.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial Scar Size</title>
          <description>Percentage of myocardial scar size proportion measured by MRI to quantify and define the extent/transmurality of scar tissue, the following definitions were used
spatial (circumferential) extent, the number of affected segments
nontransmurality, the number of segmments with a segmental scar score of 1 or 2, and transmurality, the number of segments with a segmental scar score of 3 or 4
total score, summed segmental scar scores per patient divided by 17 (which reflects the damage per patient)</description>
          <units>Percentage of Scar Area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.76" spread="15.76"/>
                    <measurement group_id="B2" value="24.45" spread="13.73"/>
                    <measurement group_id="B3" value="26.11" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial perfusion defect</title>
          <description>Number of heart wall segments with perfusion defect measured by MRI.</description>
          <units>Percentage of Myocardial Perfusion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.76" spread="4.38"/>
                    <measurement group_id="B2" value="15.38" spread="4.87"/>
                    <measurement group_id="B3" value="15.57" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wall motion score index</title>
          <description>Cardiac wall motion abnormality will be measured using Wall Motion Score Index with MRI. Each myocardial segment is assigned a score from 1 to 4. The 16 segment model of myocardial segmentation is recommended.
A WMSI of 1.0 is considered normokinetic. A WMSI of 1.5 is considered mild hypokinesia A WMSI of 2.0 is considered hypokinesia A WMSI of 2.5 is considered severe hypokinesia A WMSI of 3.0 is considered akinetic.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.32" spread="0.17"/>
                    <measurement group_id="B2" value="2.07" spread="0.31"/>
                    <measurement group_id="B3" value="2.2" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minnesotta Living with Heart Failure Score</title>
          <description>Quality of life assessed using Minnesota Living With Heart Failure Questionnaire consist of 21 questions, to see the changes before and after intervention.
Minimum score = 0, Maximum score = 105 Higher values represent a worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="13.73"/>
                    <measurement group_id="B2" value="21.46" spread="8.76"/>
                    <measurement group_id="B3" value="25.88" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vascular Endothelial Growth Factor</title>
          <description>Cytokine that has important role for angiogenesis. Normal range for plasma VEGF is 0-115 pg/ml</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.86" spread="141.20"/>
                    <measurement group_id="B2" value="40.46" spread="40.08"/>
                    <measurement group_id="B3" value="43.66" spread="101.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Defect Perfusion</title>
        <description>Number of heart wall segments with perfusion defect measured by MRI.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Defect Perfusion</title>
          <description>Number of heart wall segments with perfusion defect measured by MRI.</description>
          <units>Percentage of Myocardial Perfusion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.76" spread="4.38"/>
                    <measurement group_id="O2" value="15.38" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="2.13"/>
                    <measurement group_id="O2" value="3.85" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Ejection Fraction</title>
        <description>Left ventricular ejection fraction (LVEF) measured by MRI. Normal range of LVEF ranges from 50% to 70%. Borderline LVEF ranges from 41% to 49% Reduced LVEF ranges &lt; 41%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <description>Left ventricular ejection fraction (LVEF) measured by MRI. Normal range of LVEF ranges from 50% to 70%. Borderline LVEF ranges from 41% to 49% Reduced LVEF ranges &lt; 41%</description>
          <units>percentage of ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.88" spread="5.66"/>
                    <measurement group_id="O2" value="30.18" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.58" spread="11.32"/>
                    <measurement group_id="O2" value="31.62" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Minutes Walking Test</title>
        <description>Quality of life will be assessed using Six minutes walking test, to see the changes of six minutes walking test before and after intervention Distances reported for healthy individuals ages 40 yo 85 years range from 400 to 700 m..</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Six Minutes Walking Test</title>
          <description>Quality of life will be assessed using Six minutes walking test, to see the changes of six minutes walking test before and after intervention Distances reported for healthy individuals ages 40 yo 85 years range from 400 to 700 m..</description>
          <units>meters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299" lower_limit="260.50" upper_limit="350.00"/>
                    <measurement group_id="O2" value="298" lower_limit="255" upper_limit="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420" lower_limit="381" upper_limit="441"/>
                    <measurement group_id="O2" value="378" lower_limit="335" upper_limit="414.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wall Motion Score Index</title>
        <description>Cardiac wall motion abnormality will be measured using Wall Motion Score Index with MRI. Each myocardial segment is assigned a score from 1 to 4. The 16 segment model of myocardial segmentation is recommended.
A WMSI of 1.0 is considered normokinetic. A WMSI of 1.5 is considered mild hypokinesia A WMSI of 2.0 is considered hypokinesia A WMSI of 2.5 is considered severe hypokinesia A WMSI of 3.0 is considered akinetic.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Wall Motion Score Index</title>
          <description>Cardiac wall motion abnormality will be measured using Wall Motion Score Index with MRI. Each myocardial segment is assigned a score from 1 to 4. The 16 segment model of myocardial segmentation is recommended.
A WMSI of 1.0 is considered normokinetic. A WMSI of 1.5 is considered mild hypokinesia A WMSI of 2.0 is considered hypokinesia A WMSI of 2.5 is considered severe hypokinesia A WMSI of 3.0 is considered akinetic.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.17"/>
                    <measurement group_id="O2" value="2.07" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.43"/>
                    <measurement group_id="O2" value="2.08" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Scar Size</title>
        <description>Percentage of myocardial scar size proportion measured by MRI to quantify and define the extent/transmurality of scar tissue, the following definitions were used
spatial (circumferential) extent, the number of affected segments
nontransmurality, the number of segmments with a segmental scar score of 1 or 2, and transmurality, the number of segments with a segmental scar score of 3 or 4
total score, summed segmental scar scores per patient divided by 17 (which reflects the damage per patient)</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>subjectTransepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Scar Size</title>
          <description>Percentage of myocardial scar size proportion measured by MRI to quantify and define the extent/transmurality of scar tissue, the following definitions were used
spatial (circumferential) extent, the number of affected segments
nontransmurality, the number of segmments with a segmental scar score of 1 or 2, and transmurality, the number of segments with a segmental scar score of 3 or 4
total score, summed segmental scar scores per patient divided by 17 (which reflects the damage per patient)</description>
          <units>Percentage of Scar Area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.76" spread="15.76"/>
                    <measurement group_id="O2" value="24.45" spread="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.46" spread="12.91"/>
                    <measurement group_id="O2" value="27.32" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Endothelial Growth Factor</title>
        <description>Cytokine that has important role for angiogenesis. Normal range for plasma VEGF is 0-115 pg/ml</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Endothelial Growth Factor</title>
          <description>Cytokine that has important role for angiogenesis. Normal range for plasma VEGF is 0-115 pg/ml</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.86" spread="141.20"/>
                    <measurement group_id="O2" value="40.46" spread="40.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.05" spread="63.01"/>
                    <measurement group_id="O2" value="19.88" spread="33.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricle End Systolic Volume</title>
        <description>Left ventricle end-systolic volume is the volume of blood in a left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole.
Normal LVESV ranges is 37 - 57 mililiters.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle End Systolic Volume</title>
          <description>Left ventricle end-systolic volume is the volume of blood in a left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole.
Normal LVESV ranges is 37 - 57 mililiters.</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.87" spread="35.94"/>
                    <measurement group_id="O2" value="141.05" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op LVESV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.91" spread="86.03"/>
                    <measurement group_id="O2" value="149.33" spread="44.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Living With Heart Failure Questionnaire</title>
        <description>Quality of life assessed using Minnesota Living With Heart Failure Questionnaire consist of 21 questions, to see the changes before and after intervention.
Minimum score = 0, Maximum score = 105 Higher values represent a worse outcome</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Minnesota Living With Heart Failure Questionnaire</title>
          <description>Quality of life assessed using Minnesota Living With Heart Failure Questionnaire consist of 21 questions, to see the changes before and after intervention.
Minimum score = 0, Maximum score = 105 Higher values represent a worse outcome</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="20" upper_limit="39.5"/>
                    <measurement group_id="O2" value="23" lower_limit="15" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4.5" upper_limit="16"/>
                    <measurement group_id="O2" value="14" lower_limit="4.5" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricle End Diastolic Volume</title>
        <description>Left ventricle end-diastolic volume is the volume of blood in the left ventricle at end load or filling in (diastole) or the amount of blood in the ventricle just before systole.
Normal ranges of LVEDV is 121 - 163 mililiters</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transepicardial With Transseptal CD 133+ Implantation</title>
            <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>this arm will receive CABG only</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle End Diastolic Volume</title>
          <description>Left ventricle end-diastolic volume is the volume of blood in the left ventricle at end load or filling in (diastole) or the amount of blood in the ventricle just before systole.
Normal ranges of LVEDV is 121 - 163 mililiters</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.10" spread="47.46"/>
                    <measurement group_id="O2" value="200.89" spread="37.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op LVEDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.68" spread="94.99"/>
                    <measurement group_id="O2" value="219.97" spread="35.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subject</title>
          <description>this arm will receive CABG + Transepicardial with Transseptal CD 133+ Implantation</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>this arm will receive CABG only</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tri Wisesa Soetisna, M.D, MHA, PhD</name_or_title>
      <organization>National Cardiovascular Center Harapan Kita</organization>
      <phone>+62215684093</phone>
      <email>tricts2000@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

